SylamoreBio
SylamoreBio is a preclinical-stage biotech developing proprietary RTB lectin-based delivery platforms that transport therapeutic cargo across the blood-brain barrier to CNS and hard-to-treat tissues, partnering with pharmaceutical companies for drug discovery and development.
- Company typePrivate
- Founded2025
- HeadquartersJonesboro, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What SylamoreBio does
SylamoreBio is a privately held biotechnology company founded in 2025 and headquartered at the Catalyst Innovation Center at ABI in Jonesboro, Arkansas. The company develops a proprietary lectin-based drug delivery platform designed to transport therapeutic cargo — including enzymes, antibodies, and RNA — across biological barriers to reach tissues historically resistant to therapeutic access, with a primary focus on central nervous system (CNS) delivery via blood-brain barrier (BBB) penetration.
The company's core technology is its RTB (Ribosome-Inactivating Protein Lectin) platform, a sugar-binding lectin that targets glycans abundantly expressed on human cell surfaces to enable receptor-independent cellular uptake. A key differentiation is the platform's ability to maintain delivery efficiency even in the presence of anti-drug antibodies (ADA), which compromise conventional enzyme replacement therapies in over 90% of patients with Hurler (MPS I), MPS VIA, Pompe, and Fabry diseases. The SyLEC delivery technology extends this foundation into CNS-specific applications. Preclinical animal-model data demonstrate CNS pathology normalization, substrate clearance, neuroinflammation reduction, and improvements in memory and learning benchmarks.
SylamoreBio operates a B2B platform business model, monetizing through research collaborations and licensing/co-development partnerships with pharmaceutical companies seeking novel delivery solutions for hard-to-access tissues. The company does not sell products directly; instead, it partners with established pharmaceutical firms that contribute drug discovery and development expertise. In February 2026, SylamoreBio announced its first publicly disclosed major pharmaceutical partnership — a research collaboration with Daiichi Sankyo to advance SyLEC for CNS applications.
SylamoreBio firmographics
Firmographics- Name
- SylamoreBio
- Legal name
- SylamoreBio
- Website
- https://sylamorebio.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SylamoreBio is a preclinical-stage biotech developing proprietary RTB lectin-based delivery platforms that transport therapeutic cargo across the blood-brain barrier to CNS and hard-to-treat tissues, partnering with pharmaceutical companies for drug discovery and development.
- Ownership category
- akta.pro rank
SylamoreBio industry classification
Industry- Product category
- Biotech Drug Delivery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
Keywords
Where SylamoreBio is headquartered
LocationHeadquarters
- HQ city
- Jonesboro
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
SylamoreBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Technology Licensing and Partnership Revenue: Pre-revenue biotech company generating value through research collaborations, licensing agreements, and co-development partnerships with pharmaceutical companies. Revenue model centers on advancing the RTB platform through partnerships that leverage partner drug discovery and development expertise.
Distribution channels1 record
Marketing channels3 records
SylamoreBio product offering
Product offeringCore offering
SylamoreBio develops a proprietary RTB (Ribosome-Inactivating Protein) lectin-based delivery platform that enables efficient, receptor-independent cellular uptake of therapeutic cargo across biological barriers, including the blood-brain barrier. The platform delivers enzymes, antibodies, and RNAs to CNS, peripheral nerves, tumors, bone, and muscle tissues, and maintains efficacy in the presence of anti-drug antibodies. The company advances this technology through research collaborations and licensing partnerships with pharmaceutical companies for treating lysosomal storage disorders and other CNS diseases with unmet medical needs.
Product overview
SylamoreBio is a biotech company developing a proprietary lectin-based drug delivery platform centered on two key technologies: the RTB (Ribosome-Inactivating Protein Lectin) platform and the SyLEC delivery technology. The RTB platform is a sugar-binding lectin that enables targeted delivery of therapeutic cargo—including enzymes, antibodies, and RNAs—to hard-to-reach tissues such as the CNS, bone, and muscle, even in the presence of anti-drug antibodies. The SyLEC technology builds on this platform to advance therapeutic delivery across biological barriers, particularly the blood-brain barrier, for treating CNS diseases and other conditions with unmet medical needs.
Differentiator
Problem solved
Functional benefit
Products and services
- RTB Lectin-Mediated Delivery Platform
Quantifiable outcome
- Over 90% of patients with Hurler (MPS I), MPS VIA, Pompe and Fabry develop anti-drug antibodies to approved therapies
- +1 more outcomes
Companies that use SylamoreBio
Customer profileSegments1 record
Ideal customer profiles1 record
SylamoreBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SylamoreBio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Daiichi SankyocoreResearch collaboration to advance SylamoreBio's proprietary SyLEC delivery technology for central nervous system applications. The partnership leverages Daiichi Sankyo's drug discovery and development expertise alongside SylamoreBio's platform designed to transport therapeutic cargo across biological barriers like the blood-brain barrier. The CEO described the collaboration as significant validation of the SyLEC platform's capacity to deliver therapeutics to hard-to-reach tissues for treating diseases with unmet medical needs.
Scale indicators1 record
Recent moves4 records
Expansion highlights3 records
SylamoreBio competitors and assessment
Company assessmentDirect peers
- Vect-Horus: French biotech with a proprietary BBB delivery platform (VEC-TPP) that transports biologics and nucleic acids into the CNS — closest functional analog to SylamoreBio's RTB/SyLEC delivery thesis.
- AngioChem: Clinical-stage biotech using LRP-1 receptor-targeting peptides to shuttle therapeutics across the BBB — a directly comparable BBB-crossing delivery platform for CNS indications.
- JCR Pharmaceuticals: Japan-based biotech developing J-Brain Cargo, a transferrin-receptor-based BBB delivery platform for CNS-penetrant enzyme therapies — directly comparable BBB delivery approach in LSDs.
- Denali Therapeutics: Clinical-stage biotech developing engineered enzyme and antibody therapeutics delivered across the BBB for lysosomal storage diseases and neurodegeneration — directly comparable BBB delivery + LSD franchise.
Emerging players
- Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based CNS delivery for neurological diseases — comparable target tissues and partner-driven business model, though viral-vector based.
- Evox Therapeutics: Developer of engineered exosome-based delivery of proteins and nucleic acids across the BBB — comparable non-viral delivery approach for CNS and rare diseases.
- Generation Bio: Non-viral genetic medicines company developing lipid nanoparticle delivery of DNA and RNA to multiple tissues including CNS — comparable platform-licensing thesis for hard-to-reach tissues.
- IONTAS: UK-based protein engineering company developing antibody and protein-based therapeutics, including BBB-penetrant modalities — adjacent in protein engineering capability feeding CNS delivery.
- Passage Bio: Clinical-stage AAV gene therapy company focused on CNS disorders, including GM1 gangliosidosis — overlapping indication space (SylamoreBio has referenced GM1 in pipeline materials).
Broad incumbents
- BioMarin Pharmaceutical: Established rare disease leader with marketed enzyme replacement therapies across MPS, Pompe, and other LSDs — the incumbent whose ADA-vulnerable products SylamoreBio's platform could complement or compete with.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
SylamoreBio social profiles
Digital presenceSylamoreBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
SylamoreBio leadership team
Management profileNumber of profiles
Profiles3 records
SylamoreBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SylamoreBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SylamoreBio
What does SylamoreBio do?
SylamoreBio develops a proprietary RTB (Ribosome-Inactivating Protein) lectin-based delivery platform that enables efficient, receptor-independent cellular uptake of therapeutic cargo across biological barriers, including the blood-brain barrier. The platform delivers enzymes, antibodies, and RNAs to CNS, peripheral nerves, tumors, bone, and muscle tissues, and maintains efficacy in the presence of anti-drug antibodies. The company advances this technology through research collaborations and licensing partnerships with pharmaceutical companies for treating lysosomal storage disorders and other CNS diseases with unmet medical needs.
Is SylamoreBio a public or private company?
SylamoreBio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was SylamoreBio founded?
SylamoreBio was founded in 2025. It employs 1 to 10 people.
Where is SylamoreBio based?
SylamoreBio is headquartered in Jonesboro, United States, in the North America region.
How does SylamoreBio make money?
One revenue line is on record: technology Licensing and Partnership Revenue.
Who are SylamoreBio's main competitors?
Direct peers on record are Vect-Horus, AngioChem, JCR Pharmaceuticals and Denali Therapeutics. Emerging players are Voyager Therapeutics, Evox Therapeutics, Generation Bio, IONTAS and Passage Bio. BioMarin Pharmaceutical is listed as a broad incumbent.
Does SylamoreBio have an API?
No public API is recorded for SylamoreBio.
What industry is SylamoreBio in?
SylamoreBio's product category is Biotech Drug Delivery Platform. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 541714 and its SIC code is 8731.